Home | Welcome to Contract Pharma   
Last Updated Friday, April 25 2014
Print

Almac, TTP Form FLT Pact



Published January 7, 2013
Related Searches: Development
Almac and TTP Labtech have formed an alliance in the field of fluorescence lifetime (FLT) technology to provide enhanced screening performance. The alliance aims to provide customers with access to a broad range of biological applications coupled with the next generation of microplate reader technology.
 
According to the companies, FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform that enables the user to avoid interference from fluorescent compounds within a screening library. Almac’s FLEXYTE assays now have FLT technology to provide a more efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many therapeutic target classes including: kinases, proteases, phosphatases, DUB, and epigenetic targets.
 
TTP Labtech’s Ameon system is a next-generation FLT reader technology, offering real-time decay curve analysis, faster and more precise data quality, and can be integrated into HTS workflows, according to the company.
 
“The development of the Ameon reader by TTP Labtech has introduced an exciting new dimension to FLT technology and we are pleased that Almac’s FLEXYTE customers will be able to benefit from this advance in reader technology,” said Dr. Stephen Barr, president and managing director of Almac Sciences.
 
“We are excited by the potential of the FLEXYTE and Ameon reader combination to deliver robust, cost-effective screening results and enhanced productivity through better discrimination of lead compounds,” said Dr. Wayne Bowen, chief scientific officer of TTP Labtech.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On